Global United States Precision Medicine Market Size, Share and Trends Analysis
United States Precision Medicine market size was $38.5B in 2023, forecast to hit $87.2B by 2032, growing at a 9.5% CAGR.
$38.5B
$87.1B
9.5%
North America
Executive Summary
The United States precision medicine market was valued at approximately $38.5 billion in 2023 and is projected to reach $87.2 billion by 2032, growing at a CAGR of 9.5%. Dominated by oncology applications and NGS-based diagnostics, the market benefits from strong FDA regulatory support, rising R&D investments, and increasing adoption of AI-driven genomic profiling across hospitals, diagnostic laboratories, and pharmaceutical companies nationwide.
Key Highlights
US precision medicine market driven by oncology applications, genomic sequencing advances, and rising personalized therapy adoption across hospitals and diagnostic labs.
NGS and bioinformatics platforms dominate technology segmentation, enabling faster and more cost-effective genomic profiling for targeted treatments.
FDA's expanding companion diagnostics approvals and AI-driven drug discovery are accelerating market growth and clinical integration of precision therapies.
Market Overview
Market Context
The US precision medicine market is experiencing rapid transformation driven by declining genomic sequencing costs, expanding biomarker discovery, and increasing clinical adoption of targeted therapies across oncology, cardiology, and rare disease domains.
The US precision medicine market, valued at $38.5B in 2023, is experiencing high growth driven by genomic sequencing, companion diagnostics, and targeted therapies. Oncology leads application segments at 45% share, while NGS technology dominates the landscape.
Market Stage
High growth
Adoption Level
Growing
Key Trends
Market Forecast & Data
Base Year (2023)
$38.5B
Forecast (2032)
$87.1B
CAGR (2024-2032)
9.5%
| Year | Market size ($ Billion) |
|---|---|
| 2023Base year | $38.50B |
| 2024 | $42.16B |
| 2025 | $46.16B |
| 2026 | $50.55B |
| 2027 | $55.35B |
| 2028 | $60.61B |
| 2029 | $66.37B |
| 2030 | $72.67B |
| 2031 | $79.57B |
| 2032 | $87.13B |
With a 9.5% CAGR, the US market is projected to nearly double from $38.5B to $87.2B by 2032, fueled by liquid biopsy adoption, AI-enhanced diagnostics, and expanding companion diagnostic approvals.
| Region | Market share | Growth rate | Largest market |
|---|---|---|---|
| North America | 45.0% | 9.5% | United States |
| Europe | 30.0% | 8.2% | Germany |
| Asia Pacific | 25.0% | 12.8% | China |
North America
#1Largest market: United States
Europe
#2Largest market: Germany
Market Dynamics
- Rising prevalence of cancer and chronic diseases requiring personalized treatment
- Advances in genomic sequencing reducing per-test costs significantly
- Increased FDA approvals for companion diagnostics and targeted therapies
Market Segmentation
| Segment | Share |
|---|---|
| Genomics / Next-Generation SequencingLargest technology segment driven by declining sequencing costs and expanding clinical applications. | 35.0% |
| BioinformaticsCritical for analyzing complex genomic data and enabling AI-driven biomarker discovery. | 20.0% |
| Companion DiagnosticsGrowing alongside targeted therapies with increasing FDA CDx approvals. | 20.0% |
| Targeted TherapiesSmall-molecule inhibitors and biologics designed for genetically defined patient populations. | 15.0% |
| Gene TherapyEmerging segment with CRISPR and viral vector-based treatments gaining clinical traction. | 10.0% |
| Total | 100.0% |
| Segment | Share |
|---|---|
| OncologyLargest application area with extensive use of genomic profiling for treatment selection. | 45.0% |
| Cardiovascular DiseasesPharmacogenomics guiding anticoagulant and antiplatelet therapy decisions. | 15.0% |
| Neurological DisordersGenetic testing for Alzheimer's, Parkinson's, and rare neurological conditions. | 12.0% |
| Rare DiseasesWhole-exome and genome sequencing enabling diagnosis of previously undiagnosed conditions. | 10.0% |
| Infectious DiseasesPathogen genomics and host-response profiling for personalized antimicrobial therapy. | 8.0% |
| OthersIncludes immunology, metabolic disorders, and reproductive health applications. | 10.0% |
| Total | 100.0% |
By End User
- Hospitals
- Diagnostic Laboratories
- Research Institutes
- Pharmaceutical Companies
Regional Analysis
North America
Lead: United StatesLargest regional market driven by advanced healthcare infrastructure, strong R&D funding, and favorable regulatory environment.
Europe
Lead: GermanySecond-largest market supported by growing genomic initiatives and increasing adoption of companion diagnostics.
Asia Pacific
Lead: ChinaFastest-growing region fueled by rising healthcare expenditure, expanding genomics infrastructure, and large patient populations.
Country-Level Analysis
| Country | Share | Growth |
|---|---|---|
| United States | 42.0% | +9.5% |
| Germany | 10.0% | +8.0% |
| China | 12.0% | +14.2% |
Competitive Landscape
Roche Diagnostics
Switzerland
Dominates companion diagnostics and oncology precision medicine through Foundation Medicine and extensive CDx portfolio.
Global leader in companion diagnostics and oncology precision medicine, leveraging Foundation Medicine's comprehensive genomic profiling platforms.
Thermo Fisher Scientific
United States
Largest consumables and reagents provider; expanded into proteomics with Olink Proteomics acquisition in 2024.
World's largest provider of scientific instruments and reagents for genomic analysis, with expanding proteomics capabilities through Olink acquisition.
Illumina, Inc.
United States
Leading NGS platform provider serving millions of patients globally with comprehensive genomic sequencing solutions.
Dominant next-generation sequencing platform provider enabling large-scale genomic testing across research and clinical diagnostics worldwide.
Recent Developments
Expanded Foundation Medicine liquid biopsy capabilities with new circulating tumor DNA panels for real-time treatment monitoring.
Completed acquisition of Olink Proteomics to integrate protein-level data with genomic insights for comprehensive precision medicine solutions.
Regulatory Landscape
Research Methodology
Primary research
- Expert interviews
- Surveys
Secondary research
- Industry reports
- Company financials
Validation: Triangulation method
Strategic Takeaways
The US precision medicine market offers strong growth potential with a 9.5% CAGR, driven by oncology genomics and AI-enabled diagnostics.
Invest in NGS infrastructure, bioinformatics capabilities, and companion diagnostics to capture growing demand across hospitals and research institutes.
Frequently Asked Questions
Related research
Reports in the same field, each with its base-year figure and the growth rate it is published at.
- BiotechnologyGlobal United States Genomics Market$47.0B · 12.6% CAGR
- BiotechnologyGlobal Europe Precision Medicine Market$24.5B · 13.5% CAGR
- BiotechnologyGlobal North America Precision Medicine Market$70.0B · 12.8% CAGR
- BiotechnologyGlobal Precision Medicine Market$85.0B · 11.5% CAGR
- BiotechnologyGlobal Asia Pacific Precision Medicine Market$120.0B · 9.4% CAGR
- BiotechnologyUnited States Cell & Gene Therapy Manufacturing Market$11.4B · 34.1% CAGR